340B Drug Pricing Program
AHA urges HRSA to restore policy for 340B hospitals with new outpatient facilities.
Over the past 30 years, the 340B Drug Pricing Program has played an essential role in ensuring health care providers have the necessary resources to provide vital programs and services for underserved patients and communities. Ongoing bipartisan support of the program is critical to ensuring…
The AHA May 25 published a report on the 340B Drug Pricing Program, its history and value to hospitals and patients, and details on 340B contract pharmacy arrangements.
AHA, 340B hospitals and stakeholders voice concerns with two pieces of legislation that were recently passed out of the House Energy and Commerce Committee’s Health Subcommittee.
Learn what the HHS 340B Drug Pricing Program is and what 340B hospitals are. The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients by providing 340B drug pricing discounts and expand health services to the patients and…
AHA, others voice strong opposition to 340B proposals being considered by House E&C Committee
AHA statement on legislative proposals that are to be considered before the Energy and Commerce Committee on May 24.
The House Energy and Commerce Subcommittee on Health yesterday advanced a series of health care bills, and voted to pass and send to the full committee a bill that would impose additional reporting requirements on hospitals that participate in the 340B Drug Pricing Program.
The House Energy and Commerce Subcommittee on Health May 17 considered a series of health care bills, including a number focused on provisions that would affect hospitals and health systems.
AHA shares hospital field’s comments on legislative proposals that are to be considered before the Energy & Commerce Health Subcommittee on May 17.